EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy

Ala Dibas iD, Manuel Rhiel iD, Vidisha Bhavesh Patel iD, Geoffroy Andrieux iD, Melanie Boerries, Tatjana I Cornu, Jamal Alzubi iD, Toni Cathomen iD

Cells · 2023

DOI: 10.3390/cells12212581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Ala Dibas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany. Hauptthemen laut MEDLINE: Granulocyte-Macrophage Colony-Stimulating Factor, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, German Federal Ministry of Education and Research, German Academic Exchange Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While chimeric antigen receptor (CAR) T cell therapy has shown promising outcomes among patients with hematologic malignancies, it has also been associated with undesirable side-effects such as cytokine release syndrome (CRS). CRS is triggered by CAR T-cell-based activation of monocytes, which are stimulated via the CD40L–CD40R axis or via uptake of GM-CSF to secrete proinflammatory cytokines. Mouse models have been used to model CRS, but working with them is labor-intensive and they are not amenable to screening approaches. To overcome this challenge, we established two simple cell-based CRS in vitro models that entail the co-culturing of leukemic B cells with CD19-targeting CAR T cells and primary monocytes from the same donor. Upon antigen encounter, CAR T cells upregulated CD40L and released GM-CSF which in turn stimulated the monocytes to secrete IL-6. To endorse these models, we demonstrated that neutralizing antibodies or genetic disruption of the CD40L and/or CSF2 loci in CAR T cells using CRISPR-Cas technology significantly reduced IL-6 secretion by bystander monocytes without affecting the cytolytic activity of the engineered lymphocytes in vitro. Overall, our cell-based models were able to recapitulate CRS in vitro, allowing us to validate mitigation strategies based on antibodies or genome editing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulocyte-Macrophage Colony-Stimulating FactorReceptors, Chimeric AntigenHumansAnimalsMiceCD40 LigandCytokine Release SyndromeInterleukin-6Mice, KnockoutT-Lymphocytes

Stichwörter der Autor:innen

CD19-CAR T cellsCD40LCRISPR-Cas9CRSGM-CSFknockout

Substanzen

Granulocyte-Macrophage Colony-Stimulating FactorReceptors, Chimeric AntigenCD40 LigandInterleukin-6

Autor:innen und Institutionen

  • Institute for Transfusion Medicine and Gene Therapy, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Center for Chronic Immunodeficiency (CCI), Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Ph.D. Program, Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany.
  • Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, 79106 Freiburg, Germany.
  • Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • German Cancer Consortium (DKTK), Partner Site Freiburg, a Partnership between DKFZ and Medical Center-University of Freiburg, 79106 Freiburg, Germany.

ORCID-Profile: Ala Dibas, Manuel Rhiel, Vidisha Bhavesh Patel, Geoffroy Andrieux, Jamal Alzubi, Toni Cathomen

Förderung

  • European Union
  • German Federal Ministry of Education and Research
  • German Academic Exchange Service
  • erman Federal Ministry of Education and Research (BMBF)
  • institutional funds
  • Open Access Publication Fund of the University of Freiburg, Germany

Zitieren

APA

Dibas, A., Rhiel, M., Patel, V. B., Andrieux, G., Boerries, M., Cornu, T. I., Alzubi, J., & Cathomen, T. (2023). Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy. Cells. https://doi.org/10.3390/cells12212581

Vancouver

Dibas A, Rhiel M, Patel VB, Andrieux G, Boerries M, Cornu TI, et al. Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy. Cells. 2023. doi:10.3390/cells12212581

BibTeX
@article{Dibas2023,
  author = {Dibas, Ala and Rhiel, Manuel and Patel, Vidisha Bhavesh and Andrieux, Geoffroy and Boerries, Melanie and Cornu, Tatjana I and Alzubi, Jamal and Cathomen, Toni},
  title = {Cell-Based Models of ‘Cytokine Release Syndrome’ Endorse CD40L and Granulocyte–Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12212581}
}
Kostenlos starten →